Jay R.  Luly net worth and biography

Jay Luly Biography and Net Worth

Dr. Luly joined Enanta in July 2003. Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Before joining Oxford in March 2002, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium’s merger with LeukoSite, Inc., where he had served as Senior Vice President, Drug Discovery and Preclinical Development. Prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. Dr. Luly received a B.S. from the University of Illinois, Urbana/Champaign and a Ph.D. in synthetic organic chemistry from the University of California, Berkeley.

What is Jay R. Luly's net worth?

The estimated net worth of Jay R. Luly is at least $12.39 million as of December 5th, 2023. Dr. Luly owns 806,793 shares of Enanta Pharmaceuticals stock worth more than $12,392,340 as of April 16th. This net worth evaluation does not reflect any other assets that Dr. Luly may own. Additionally, Dr. Luly receives a salary of $1,250,000.00 as CEO at Enanta Pharmaceuticals. Learn More about Jay R. Luly's net worth.

How old is Jay R. Luly?

Dr. Luly is currently 68 years old. There are 6 older executives and no younger executives at Enanta Pharmaceuticals. Learn More on Jay R. Luly's age.

What is Jay R. Luly's salary?

As the CEO of Enanta Pharmaceuticals, Inc., Dr. Luly earns $1,250,000.00 per year. Learn More on Jay R. Luly's salary.

How do I contact Jay R. Luly?

The corporate mailing address for Dr. Luly and other Enanta Pharmaceuticals executives is 500 ARSENAL STREET, WATERTOWN MA, 02472. Enanta Pharmaceuticals can also be reached via phone at (617) 607-0800 and via email at [email protected]. Learn More on Jay R. Luly's contact information.

Has Jay R. Luly been buying or selling shares of Enanta Pharmaceuticals?

Jay R. Luly has not been actively trading shares of Enanta Pharmaceuticals over the course of the past ninety days. Most recently, Jay R. Luly sold 7,230 shares of the business's stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $9.63, for a transaction totalling $69,624.90. Following the completion of the sale, the chief executive officer now directly owns 806,793 shares of the company's stock, valued at $7,769,416.59. Learn More on Jay R. Luly's trading history.

Who are Enanta Pharmaceuticals' active insiders?

Enanta Pharmaceuticals' insider roster includes Nathalie Adda (VP), Jay Luly (CEO), and Paul Mellett, Jr. (Sr. VP of Fin. & Admin. and CFO ). Learn More on Enanta Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Enanta Pharmaceuticals?

During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 27,596 shares worth more than $257,949.03. The most recent insider tranaction occured on December, 13th when Director Terry Vance sold 15,295 shares worth more than $139,490.40. Insiders at Enanta Pharmaceuticals own 13.6% of the company. Learn More about insider trades at Enanta Pharmaceuticals.

Information on this page was last updated on 12/13/2023.

Jay R. Luly Insider Trading History at Enanta Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2023Sell7,230$9.63$69,624.90806,793View SEC Filing Icon  
3/13/2023Sell27,912$45.16$1,260,505.92819,810View SEC Filing Icon  
12/16/2022Sell30,000$44.72$1,341,600.00773,805View SEC Filing Icon  
9/15/2021Sell4,516$59.06$266,714.96View SEC Filing Icon  
7/6/2018Sell35,000$125.24$4,383,400.00625,049View SEC Filing Icon  
5/17/2018Sell25,000$105.83$2,645,750.00638,994View SEC Filing Icon  
3/9/2015Sell15,000$33.37$500,550.00View SEC Filing Icon  
2/20/2015Sell15,000$35.35$530,250.00View SEC Filing Icon  
1/5/2015Sell15,000$50.43$756,450.00View SEC Filing Icon  
12/1/2014Sell15,000$45.39$680,850.00View SEC Filing Icon  
11/3/2014Sell15,000$42.52$637,800.00View SEC Filing Icon  
1/2/2014Sell5,800$28.05$162,690.00View SEC Filing Icon  
See Full Table

Jay R. Luly Buying and Selling Activity at Enanta Pharmaceuticals

This chart shows Jay R Luly's buying and selling at Enanta Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Enanta Pharmaceuticals Company Overview

Enanta Pharmaceuticals logo
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $15.36
Low: $15.33
High: $16.13

50 Day Range

MA: $14.69
Low: $12.26
High: $17.46

2 Week Range

Now: $15.36
Low: $8.08
High: $38.79


211,027 shs

Average Volume

267,198 shs

Market Capitalization

$325.02 million

P/E Ratio


Dividend Yield